AIGH Capital reports 5.9% Grace Therapeutics (GRCE) ownership stake

Rhea-AI Filing Summary

Grace Therapeutics, Inc. received an amended Schedule 13G/A showing that AIGH Capital Management LLC, AIGH Investment Partners LLC, and Orin Hirschman together report beneficial ownership of 907,217 shares of Common Stock, representing 5.9% of the class as of 12/31/2025.

The filing notes an additional 824,742 common shares are issuable upon exercise of warrants that are not currently exercisable because of beneficial ownership limitations. The reporting persons certify the shares were acquired and are held in the ordinary course of business and not to change or influence control of Grace Therapeutics.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

Grace Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

00439U104

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 00439U104

1

Names of Reporting Persons

Orin Hirschman

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 907,217.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 907,217.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

907,217.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.9 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP No. 00439U104

1

Names of Reporting Persons

AIGH Capital Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 907,217.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 907,217.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

907,217.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.9 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Grace Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 103 Carnegie Center, Suite 300, Princeton, NJ, 08540
Item 2.
(a)	Name of person filing: This Schedule 13G is being jointly filed by each of the following persons pursuant to Rule 13d-1 promulgated by the Securities and Exchange Commission pursuant to Section 13 of the Securities Exchange Act of 1934, as amended (the "Act"): (i) AIGH Capital Management, LLC, a Maryland limited liability company ("AIGH CM"), as an Advisor or Sub-Advisor with respect to shares of Common Stock (as defined in Item 2(d) below) held by AIGH Investment Partners, L.P., and WVP Emerging Manger Onshore Fund, LLC - AIGH Series. (ii) AIGH Investment Partners, L.L.C., a Delaware limited liability company ("AIGH LLC";), with respect to shares of Common Stock (as defined in Item 2(d) below) directly held by it; (iii) Mr. Orin Hirschman ("Mr. Hirschman"), who is the Managing Member of AIGH Capital Management, LLC and president of AIGH LLC, with respect to shares of Common Stock (as defined in Item 2(d) below) indirectly held through AIGH CM, directly by AIGH LLC and Mr. Hirschman and his family directly. AIGH Capital Management LLC., AIGH Investment Partners LLC, and Mr. Hirschman are hereinafter sometimes collectively referred to as the "Reporting Persons." Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.
(b)	Address or principal business office or, if none, residence: The principal office and business address of AIGH Capital Management LLC, AIGH Investment Partners LLC, and Mr.Hirschman is: 6006 Berkeley Avenue, Baltimore MD 21209
(c)	Citizenship: See Item 2(a) above and Item 4 of each cover page.
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 00439U104
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 907,217 Excludes 824,742 common shares issuable upon exercise of warrants not currently exercisable due to beneficial ownership limitations on exercise
(b)	Percent of class: 5.9 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 907,217
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 907,217 Excludes 824,742 common shares issuable upon exercise of warrants not currently exercisable due to beneficial ownership limitations on exercise
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Orin Hirschman

Signature:	/s/ Orin Hirschman
Name/Title:	Orin Hirschman
Date:	01/28/2026

AIGH Capital Management LLC

Signature:	/s/ Orin Hirschman
Name/Title:	Orin Hirschman, Managing Member
Date:	01/28/2026

FAQ

What percentage of Grace Therapeutics (GRCE) does AIGH Capital report owning?

AIGH Capital Management LLC, AIGH Investment Partners LLC, and Orin Hirschman together report beneficial ownership of 5.9% of Grace Therapeutics’ common stock. This corresponds to 907,217 shares, as disclosed in the amended Schedule 13G/A with an event date of December 31, 2025.

How many Grace Therapeutics (GRCE) shares are beneficially owned according to this Schedule 13G/A?

The reporting persons disclose beneficial ownership of 907,217 shares of Grace Therapeutics common stock. They report sole voting and dispositive power over these shares, with no shared voting or dispositive power, resulting in a reported ownership stake of 5.9% of the outstanding common stock.

Are there additional Grace Therapeutics (GRCE) shares tied to warrants in this filing?

Yes. The filing states that ownership figures exclude 824,742 common shares issuable upon exercise of warrants. These warrants are not currently exercisable because of beneficial ownership limitations on exercise, so those potential shares are not counted in the reported 5.9% stake.

Who are the reporting persons in the Grace Therapeutics (GRCE) Schedule 13G/A?

The Schedule 13G/A is jointly filed by AIGH Capital Management LLC, AIGH Investment Partners LLC, and Orin Hirschman. Hirschman is described as the Managing Member of AIGH Capital Management LLC and president of AIGH Investment Partners LLC, and they are collectively referred to as the reporting persons.

What does the Schedule 13G/A say about AIGH’s intent regarding control of Grace Therapeutics (GRCE)?

The certification states the securities were acquired and are held in the ordinary course of business. It further states they were not acquired and are not held for the purpose or effect of changing or influencing control of Grace Therapeutics, consistent with a passive ownership filing.

What is the event date referenced in this Grace Therapeutics (GRCE) ownership filing?

The Schedule 13G/A lists an event date of December 31, 2025. This date indicates the point as of which the reported beneficial ownership information applies, including the 907,217 shares and corresponding 5.9% ownership of Grace Therapeutics’ outstanding common stock.